key: cord-0991107-bu0xdp3l
authors: Merckx, Joanna; Morris, Shaun K.; Bitnun, Ari; Gill, Peter; El Tal, Tala; Laxer, Ronald M.; Yeh, Ann; Yea, Carmen; Ulloa-Gutierrez, Rolando; Brenes-Chacon, Helena; Yock-Corrales, Adriana; Ivankovich-Escoto, Gabriela; Soriano-Fallas, Alejandra; Hernandez-de Mezerville, Marcela; Papenburg, Jesse; Lefebvre, Marie-Astrid; Nateghian, Alireza; Haghighi Aski, Behzad; Manafi, Ali; Dwilow, Rachel; Bullard, Jared; Cooke, Suzette; Dewan, Tammie; Restivo, Lea; Lopez, Alison; Sadarangani, Manish; Roberts, Ashley; Barton, Michelle; Petel, Dara; Le Saux, Nicole; Bowes, Jennifer; Purewal, Rupeena; Lautermilch, Janell; Tehseen, Sarah; Bayliss, Ann; Wong, Jacqueline K.; Viel-Thériault, Isabelle; Piche, Dominique; Top, Karina A.; Leifso, Kirk; Foo, Cheryl; Panetta, Luc; Robinson, Joan
title: Infants hospitalized for acute COVID-19: disease severity in a multicenter cohort study
date: 2022-02-25
journal: Eur J Pediatr
DOI: 10.1007/s00431-022-04422-x
sha: 0bbd7844fb170b7f8132c90f09690b789d9df907
doc_id: 991107
cord_uid: bu0xdp3l

Age is the most important determinant of COVID-19 severity. Infectious disease severity by age is typically J-shaped, with infants and the elderly carrying a high burden of disease. We report on the comparative disease severity between infants and older children in a multicenter retrospective cohort study of children 0 to 17 years old admitted for acute COVID-19 from February 2020 through May 2021 in 17 pediatric hospitals. We compare clinical and laboratory characteristics and estimate the association between age group and disease severity using ordinal logistic regression. We found that infants comprised one-third of cases, but were admitted for a shorter period (median 3 days IQR 2–5 versus 4 days IQR 2–7), had a lower likelihood to have an increased C-reactive protein, and had half the odds of older children of having severe or critical disease (OR 0.50 (95% confidence interval 0.32–0.78)). Conclusion: When compared to older children, there appeared to be a lower threshold to admit infants but their length of stay was shorter and they had lower odds than older children of progressing to severe or critical disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00431-022-04422-x.

The distribution of infectious disease severity by age is typically J-shaped [1] . Amongst children, neonates and infants have a high burden of disease [2] , particularly with respiratory pathogens, and have the highest hospitalization rates [3] . The objective of this study was to determine whether this is true for coronavirus disease 2019 (COVID-19) in hospitalized children.

Seventeen pediatric hospitals (15 Canadian and one each in Iran and Costa Rica) included children up to 17 years of age, admitted February 1, 2020, through May 31, 2021, with detection of SARS-CoV-2. Patients with incidental SARS-CoV-2 infection (it was not the reason for admission and did not prolong hospitalization) or who met World Health Organization (WHO) criteria for multisystem inflammatory syndrome in children (MIS-C) [4] were excluded as acute COVID-19 was not the reason for admission. Following ethics approval at all sites, data were extracted into REDCap from medical records including demographics, role of SARS-CoV-2 in admission, comorbidities (prematurity, malignancy, asthma, chronic pulmonary, heart or renal disease, obesity, or significant congenital anomalies), antibiotic use, clinical presentation, and course.

Cases were defined as mild (ward admission without supplemental oxygen), severe (ward admission with supplemental oxygen), or critical (admission to ICU or death) [5] .

Children were divided into infants (up to 11 months of age) versus older children for the primary analysis. For those older than 90 days, only month of birth was recorded, so age was the number of months between the birth and admission month. Sensitivity analyses assessed outcomes (i) in three age groups: up to 29 days, 30 days to 11 months, and 12 months or older and (ii) in infants 0 to 5 months versus 6 to 11 months old.

Descriptive statistics were used to summarize baseline characteristics of patients and comparative statistics was performed applying Kruskal-Wallis and chi-square test. Associations between age group and disease severity were examined using ordinal logistic regression in STATA 13 (StataCorp), estimating the odds of mild versus severe or critical disease.

There were 117 (36%) infants and 207 (64%) older children admitted for COVID-19 ( Fig. 1 ) after incidental SARS-CoV-2 (N = 346) and MIS-C cases (N = 144) were excluded (Supplement Flow Chart Fig. 1 ). Eighty-six infants (74%) had no comorbidities, of which 55 (64%) had mild, 18 (21%) severe, and 13 (15%) critical disease, compared to 57 (28%) older children, including 32 (56%) with mild, 13 (23%) with severe, and 12 (21%) having critical disease. One older child with severe disease was admitted to ICU for reasons unrelated to COVID-19.

Of 31 (26%) infants with comorbidities, 15 (48%) had mild, 7 (23%) severe, and 9 (29%) critical disease. This contrasted to 150 (72%) older children with comorbidities, with mild, severe, and critical disease in 55 (37%), 45 (30%), and 50 (33%), respectively.

Symptoms attributable to COVID-19 were similar in infants versus older children (Table 1) . CRP was much more likely to be elevated in older children than in infants (67% versus 15%; p-value < 0.0001). Similar proportions received antibiotics (67% of infants versus 60% of older children) ( Table 1) . The indication was possible bacterial pneumonia in 21% of infants given antibiotics versus 36% of older children. Bacterial coinfection was confirmed in 9 infants (8%) versus 6 older children (3%). Proportions of confirmed viral co-infection were similar in infants and older children, 8% and 9%, respectively.

Length of stay was shorter in infants (median 3 days IQR 2-5 versus 4 days IQR 2-7) (p-value = 0.0043). For infants, the odds of having severe or critical disease was half that of older children (OR 0.50 (95%CI 0.32-0.78)). Compared to older children, the ORs for infants up to 29 days old and 30 days to 11 months were 0.56 (95%CI 0.28-1.11) and 0.48 (95%CI 0.29-0.79), respectively. There was insufficient evidence for differing disease severity in infants up to 5 months versus 6 to 11 months old (Supplement). Six deaths occurred in children 14 months to 9 years old; all had comorbidities. 

Over one-third of children admitted with acute COVID-19 were infants, in a period with wide circulation of wildtype virus and of the variants-of-concern alpha and delta. However, the proportion of infants with severe or critical disease was lower than for older children. As far as we are aware, this is the first study to directly compare the severity of illness in hospitalized infants versus older children. Previous studies that analyzed the severity in admitted infants reported that only 4 of 34 symptomatic infants up to 90 days of age had severe or critical disease [6] and that only 1 of 14 infants was critically ill [7] .

CRP was much more likely to be elevated in older children than in infants (67% versus 15%). CRP is a sensitive marker of inflammation even in neonates [8, 9] so we hypothesize a lower level of measurable inflammation in infants compared to older children admitted with COVID-19, but it may reflect admission of infants with milder disease. Less inflammation might partially explain why infants accounted for only 4% of MIS-C cases in a large series [10] .

Limitations are that this study is not population based and investigated children admitted primarily to tertiary care centers. The threshold is presumably lower to admit infants versus older children with a similar severity of illness, especially if they are febrile and less than 90 days old [11] . This may explain why admitted infants in our study had less severe disease than did older children. Insufficient power prevents us to provide evidence for the rare outcome of mortality and for additional and more specific age and other subgroups. Furthermore, when the outcome is common, OR's calculated cannot be interpreted as risks.

In conclusion, contrary to what is observed in most other infectious diseases [1] , SARs-CoV-2 infection is not more severe in infants admitted with acute COVID-19 compared to older children.

The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s00431-022-04422-x.

The study was made possible thanks to the collaboration of the Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) and the manuscript was written on behalf of PICNIC.

Authors' contributions Dr. Merckx analyzed the data and reviewed and revised the manuscript. Dr. Barton conceptualized and designed the study, collected data, and reviewed and revised the manuscript. Drs. Morris, Bitnun, Gill, El Tal, Laxer, Yeh, Yea, Ulloa-Gutierrez, Brenes-Chacon, Yock-Corrales, Ivankovich-Escoto, Soriano-Fallas, Hernandez-de Mezerville, Papenburg, Lefebvre, Nateghian, Aski, Manafi, Dwilow, Bullard, Cooke, Dewan, Restivo, Lopez, Sadarangani, Roberts, Petel, Le Saux, Bowes, Purewal, Lautermilch, Tehseen, Bayliss, Wong, Viel-Thériault, Piche, Top, Leifso, Foo, and Panetta collected data and reviewed and revised the manuscript. Dr. Robinson conceptualized and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Availability of data and material The data are not publicly available.

The codes are available on request.

Ethics approval This study was performed in line with the principles of the Declaration of Helsinki. Ethics approval was obtained primarily at the University of Alberta (Pro00099426) and sequentially from all participating sites.

Consent for publication Not applicable. 

Systematic analysis of infectious disease outcomes by age shows lowest severity in school-age children

Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study

Trends in Infectious Disease Hospitalizations in US Children

Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19

For COVID or With COVID: classification of SARS-CoV-2 hospitalizations in children

COVID-19 disease in infants less than 90 days: case series

Severe coronavirus disease-2019 in children and young adults in the Washington DC Metropolitan Region

Value of a single C-reactive protein measurement at 18 h of age

Use of C-reactive protein to tailor antibiotic use: a systematic review and meta-analysis

Multisystem inflammatory syndrome in infants< 12 months of age

Evaluation and management of well-appearing febrile infants 8 to 60 days old